BP, pruritus, particularly associated with Alogliptin and Sitagliptin, fixed drug eruptions primarily linked to Vildagliptin and Sitagliptin, and occurrences of drug reaction with eosinophilia and systemic symptoms (DRESS) and other skin reactions such as angioedema and photosensitivity have been identified as the most prevalent cutaneous adverse reactions associated with DPP-4 inhibitors in the reviewed literature. The gene discussed is DPP4; the disease is Pruritus.